Hematology Frontier

In recent years, the field of hematologic oncology has seen numerous encouraging breakthroughs, with Chinese scholars increasingly contributing to research in cell therapy, significantly advancing the development of both the discipline and clinical practice. Hematology Frontier specially invited Dr. Ou Bai from The First Bethune Hospital of Jilin University to discuss the progress in the diagnosis and treatment of peripheral T-cell lymphoma (PTCL) in 2024. Dr. Ou Bai shared the groundbreaking advancements in PTCL treatment this year, provided insights into the innovative explorations at their hospital, and offered a forward-looking perspective on new methods and drugs in PTCL therapy.

The curtains have closed on another enlightening EHA Congress, a beacon of innovation in hematology. This year's gathering was a testament to the relentless pursuit of medical advancement, with a…

On August 19th, we honor the incredible dedication and compassion of doctors who work tirelessly to safeguard our health. Let's take a moment to appreciate their unwavering commitment to preserving…

In the vast river of life, blood flows like an unceasing stream, nourishing every inch of land and supporting the vitality and vigor of every life. Anemia, a seemingly inconspicuous…

Introduction: In this era of information explosion, how can one quickly access the latest developments in the field? Here, we select the latest literature in the field every month, focusing…

In the field of myelofibrosis treatment, allogeneic hematopoietic stem cell transplantation (allo-HSCT) serves as a curative approach, and the optimization of related strategies is particularly crucial. Recently, at the 12th…

Phototoxicity and liver damage are significant challenges for individuals with Erythropoietic Protoporphyria (EPP), a rare genetic disorder caused by the accumulation of protoporphyrin IX (PPIX). At ASH 2024, Bhavik Shah…

A recent study presented at hashtag#ASH2024 explores the mechanistic insights and clinical implications of a widely prevalent GRK5 variant affecting platelet function. featuring Yanki Yarman, this research highlights how the…

New findings presented at ASH2024 suggest that a ketogenic diet and its key metabolite, β-hydroxybutyrate (BHB), may improve CAR T-cell antitumor function. In preclinical models, BHB fueled CAR T-cell metabolism,…

Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, with FLT3 mutations among the most common molecular abnormalities, significantly impacting patient prognosis. As our understanding of AML pathogenesis deepens, novel targeted therapies, including FLT3 inhibitors, have emerged, offering new hope for patients with FLT3-mutated AML. From January 17 to 19, 2025, the "CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting & 2025 CSCO Hematologic Oncology Conference" was held in Haikou, China. During the event, Hematology Frontier had the privilege of interviewing Dr. Hui Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. He shared insights into the prevalence of FLT3 mutations in AML, recent advancements in targeted therapy, and future optimization strategies.